Perimeter Medical Imaging Closes Oversubscribed $C4.4M Financing

TORONTO, ON / ACCESSWIRE / August 21, 2019 / Perimeter Medical Imaging, Inc., the leader in real-time tissue imaging in the operating suite is pleased to announce the completion of a pre-public financing round raising $C4.4million. Perimeter intends to go public via a reverse takeover (RTO) with New World Resources (NW) in Q4 of this year. Funds raised in this pre-public round and anticipated RTO will support the commercialization of Perimeter’s U.S. Food and Drug Administration (FDA) cleared OTISTM medical imaging technology. OTISTM is deployed in the surgical suite, empowering surgeons with real-time tissue imaging to help optimize cancer surgery outcomes.

“We are pleased to have broadened our investor base and garnered additional investment from existing investors,” said Andrew Berkeley, Perimeter co-founder. “These funds will be deployed as we begin commercial operations in the US.”

Perimeter and New World have previously disclosed the terms of the RTO. Further description will be provided in a joint management information circular. The parties currently expect the RTO to close in the fourth quarter of 2019.

About Perimeter Medical Imaging, Inc.: Perimeter Medical develops, patents, and commercializes advanced in-procedural medical imaging tools. The OTIS™ platform provides clinicians with real-time, ultra-high resolution, sub-surface image volumes of the margin (1-2 mm below the surface) of an excised tissue specimen. The ability to visualize microscopic tissue structures during the clinical procedure has the potential to result in better long-term outcomes for patients and lower costs to the healthcare system.

Contact:
contact@perimetermed.com

647-360-0302

SOURCE: Perimeter Medical Imaging

View source version on accesswire.com:
https://www.accesswire.com/556900/Perimeter-Medical-Imaging-Closes-Oversubscribed-C44M-Financing

Staff

Recent Posts

Health Care AI Initiative Launched by Paragon Health Institute

New initiative will promote AI policies and solutions to transform American health careWASHINGTON, Jan. 12,…

12 minutes ago

Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound

Agreement expands Amphastar's proprietary peptide pipeline into broader inflammatory and autoimmune conditions RANCHO CUCAMONGA, CA…

12 minutes ago

CelLBxHealth PLC Announces Board Changes

GUILDFORD, SURREY / ACCESS Newswire / January 12, 2026 / CelLBxHealth plc (AIM:CLBX), a leader…

3 hours ago

Cosmo Enters Scale Up Phase with 104M Revenue, 128M Cash, and Breakout AI and Dermatology Platforms

Ad hoc announcement pursuant to Art. 53 LR 2025 marks a key execution year in…

4 hours ago

Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope

Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…

18 hours ago